Phase II study to assess the safety and efficacy of multiple treatment cycles of ImmunoPulse® IL-12 monotherapy in patients with in-transit cutaneous and subcutaneous metastatic melanoma. Patients are currently being enrolled into an extension arm of the study to evaluate a new six-week treatment cycle.
Phase II study to evaluate the safety and efficacy of ImmunoPulse® IL-12 in combination with Merck’s KEYTRUDA® (pembrolizumab) in patients with advanced metastatic melanoma.
Phase II pilot study to evaluate the ability of ImmunoPulse® IL-12 to promote an immunogenic tumor microenvironment in advanced recurrent triple negative breast cancer (TNBC).
Orange = Monotherapy with IL-12 | Green = Combination Therapy | Blue = New Combination Molecule Candidate